Heterodimer proteins

Heterodimer proteins with optimized amino acid mutations at specific positions address the challenge of maintaining FcγRIIIA binding and manufacturability, providing improved multispecific antibodies with enhanced therapeutic efficacy.

JP7842011B2Active Publication Date: 2026-04-07AGENUS INC
2 Cites 0 Cited by

Patent Information

Application Number
JP2022519303
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-27
Filing Date
2020-09-28
Publication Date
2026-04-07
Estimated Expiration
2040-09-28

AI Technical Summary

Technical Problem

Existing multispecific antibodies face challenges in achieving enhanced binding to FcγRIIIA while maintaining good manufacturability, as combining certain Fc mutations for heterodimerization and FcγRIIIA binding can adversely impact manufacturability.

Method used

The development of heterodimer proteins with specific amino acid mutations at positions 239, 332, and 366 for the first Fc polypeptide, and positions 239, 366, 368, and 407 for the second Fc polypeptide, optimized to enhance FcγRIIIA binding and manufacturability, while omitting certain amino acids like glutamic acid at position 332.

Benefits of technology

The heterodimer proteins exhibit improved binding to FcγRIIIA and maintain good manufacturability, offering enhanced therapeutic potential as multispecific antibodies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to human Fc gamma receptor IIIA (FcγRIIIA) compared to naturally occurring antibodies and retain good manufacturability. Such heterodimeric proteins are particularly useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for producing these heterodimeric proteins.
Need to check novelty before this filing date? Find Prior Art